A Study of LY3361237 in Healthy Participants
| Status: | Recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 12/6/2018 |
| Start Date: | October 26, 2018 |
| End Date: | August 29, 2019 |
| Contact: | This is a single site clinical trial. -877-CTLILLY (1-877-285-4559) or |
| Email: | ClinicalTrials.gov@lilly.com |
| Phone: | 1-317-615-4559 |
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3361237 in Healthy Subjects
The purposes of this study are to determine:
- The safety of LY3361237 and any side effects that might be associated with it.
- How much LY3361237 gets into the blood stream and how long it takes the body to remove
it in healthy participants.
Participants will be admitted to the clinical research unit (CRU) for 4 overnight stays. The
study will last about 12 weeks for each participant, not including screening.
- The safety of LY3361237 and any side effects that might be associated with it.
- How much LY3361237 gets into the blood stream and how long it takes the body to remove
it in healthy participants.
Participants will be admitted to the clinical research unit (CRU) for 4 overnight stays. The
study will last about 12 weeks for each participant, not including screening.
Inclusion Criteria:
- Healthy males or females, as determined by medical history and physical examination.
- To qualify as Japanese for this study, the participant, the participant's biological
parents, and all of the participant's biological grandparents must be of exclusive
Japanese descent and born in Japan.
- Between 18 (20 for Japanese participants) and 65 years of age.
- Have a body mass index of 18.0 to 32.0 kilograms per meter squared, inclusive, and a
minimum body weight of 45.0 kilograms.
Exclusion Criteria:
- Show evidence of active or latent tuberculosis (TB), as documented by medical history
and examination, chest x-ray and TB testing
- Are immunocompromised
- Have evidence of chronic viral infection have received live vaccine(s) (including
attenuated live vaccines) within 28 days of screening or intend to receive during the
study (non-live or inactivated vaccinations are allowed). Bacillus Calmette-Guérin
(BCG) vaccine must not have been administered within 12 months of screening
- Have had lymphoma, leukemia, or any malignancy or pre-malignant condition within the
past 5 years except for basal cell or squamous epithelial carcinomas of the skin that
have been resected with no evidence of metastatic disease for 3 years
We found this trial at
1
site
Glendale, California 91206
Principal Investigator: Hakop Gevorkyan
Phone: 818-254-1624
Click here to add this to my saved trials
